دورية أكاديمية
Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry.
| العنوان: | Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry. |
|---|---|
| المؤلفون: | Burns EA; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Wilson JJ; Trinity School of Medicine, 925 Woodstock Road, Ste 200, GA, Roswell, USA., Mathur S; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Kieser R; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Gong Z; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Hu CA; Center for Translational Research in Hematologic Malignancies, Neal Cancer Center, Houston Methodist Research Institute, 6550 Fannin St, Houston, TX, 77030, USA., Tang CA; Center for Translational Research in Hematologic Malignancies, Neal Cancer Center, Houston Methodist Research Institute, 6550 Fannin St, Houston, TX, 77030, USA., Petkova J; Department of Academic Medicine, Houston Methodist Hospital, 6550 Fannin St Ste. 1001, Houston, TX, 77030, USA., Yuen C; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Mai H; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Shah S; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Rice L; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA.; Department of Academic Medicine, Houston Methodist Hospital, 6550 Fannin St Ste. 1001, Houston, TX, 77030, USA., Ganguly S; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA., Pingali SR; Neal Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor., Houston, TX, 77030, USA. SPingali@houstonmethodist.org. |
| المصدر: | Annals of hematology [Ann Hematol] 2023 Oct; Vol. 102 (10), pp. 2753-2763. Date of Electronic Publication: 2023 Jul 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin ; New York : Springer International, c1991- |
| مواضيع طبية MeSH: | Burkitt Lymphoma*/drug therapy , Burkitt Lymphoma*/epidemiology, Humans ; Aged ; Texas/epidemiology ; Registries |
| مستخلص: | Burkitt lymphoma (BL) is an extremely aggressive but curable subtype of non-Hodgkin lymphoma. While younger patients have excellent outcomes in response to aggressive chemoimmunotherapy, the rarity of this disease in older patients and limitations caused by age, comorbidities, and performance status may negate survival advantages. This analysis assessed outcomes of older adults with BL through data provided by the Texas Cancer Registry (TCR). Patients ≥65 years with BL were assessed. Patients were dichotomized into 1997-2007 and 2008-2018. Median overall survival (OS) and disease-specific survival (DSS) were assessed using Kaplan-Meier methodology, and covariates including age, race, sex, stage, primary site, and poverty index were analyzed using Pearson Chi-squared analysis. Odds ratio (OR) with 95% confidence intervals (CI) was used to assess factors contributing to patients not offered systemic therapy. P value <0.05 was considered statistically significant. Non-BL mortality events were also categorized. There were 325 adults, 167 in 1997-2007 and 158 in 2008-2018; 106 (63.5%) and 121 (76.6%) received systemic therapy, a trend that increased with time (p = 0.010). Median OS for 1997-2007 and 2008-2018 was 5 months (95% CI 2.469, 7.531) and 9 months (95% CI 0.000, 19.154) (p = 0.013), and DSS was 72 months (95% CI 56.397, 87.603) (p = 0.604) and not reached, respectively. For patients that received systemic therapy, median OS was 8 months (95% CI 1.278, 14.722) and 26 months (95% CI 5.824, 46.176) (p = 0.072), respectively, and DSS was 79 months (95% CI: 56.416, 101.584) and not reached, respectively (p = 0.607). Age ≥75 years (HR 1.39 [95% CI 1.078, 1.791], p = 0.011) and non-Hispanic whites (HR 1.407 [95% CI 1.024, 1.935], p = 0.035) had poorer outcomes, and patients at the 20-100% poverty index (OR 0.387 [95% CI 0.163, 0.921], p = 0.032) and increasing age at diagnosis (OR 0.947 [95% CI 0.913, 0.983], p = 0.004) were less likely to receive systemic therapy. Of 259 (79.7%) deaths, 62 (23.9%) were non-BL deaths, and 6 (9.6%) of these were from a second cancer. This two-decade analysis of older Texas patients with BL indicates a significant improvement in OS over time. Although patients were more likely to receive systemic therapy over time, treatment disparities existed in patients residing in poverty-stricken regions of Texas and in advancing age. These statewide findings reflect an unmet national need to find a systemic therapeutic strategy that can be tolerated by and augment outcomes in the growing elderly population. (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Lu J, Tan H, Li B, Chen S, Xu L, Zou Y (2020) Status and prognostic nomogram of patients with Burkitt lymphoma. Oncol Lett 19(1):972–984. https://doi.org/10.3892/ol.2019.11155. (PMID: 10.3892/ol.2019.1115531897210) Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R (2016) Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 8:11–29. https://doi.org/10.2147/AHMT.S94170. (PMID: 10.2147/AHMT.S94170280966985207020) Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G (2012) Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol 87(1):22–25. https://doi.org/10.1002/ajh.22189. (PMID: 10.1002/ajh.2218922086870) Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569–1580. https://doi.org/10.1002/cncr.21776. (PMID: 10.1002/cncr.2177616502413) Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol 156(2):234–244. https://doi.org/10.1111/j.1365-2141.2011.08947.x. (PMID: 10.1111/j.1365-2141.2011.08947.x22098541) Ribrag V, Koscielny S, Bouabdallah K, Salles G, Casasnovas O, Recher C, Gressin R, Cornillon J, Herbrecht R, Lacobelli S, Bosq J, Coiffier B (2012) Addition of Rituximab improves outcome of HIV negative patients with Burkitt lymphoma treated with the Lmba protocol: results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 protocol. (IGR sponsored LMBA02, NCT00180882). Blood 120(21):685. https://doi.org/10.1182/blood.V120.21.685.685. (PMID: 10.1182/blood.V120.21.685.685) Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y (2021) Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 137(3):374–386. https://doi.org/10.1182/blood.2020006926. (PMID: 10.1182/blood.2020006926326632928765121) Texas Health and Human Services (2021) About the Texas cancer registry, accessed 15 December 2021, https://www.dshs.texas.gov/tcr/about.aspx . Liu ZL, Liu PP, Bi XW, Lei DX, Wang Y, Li ZM, Jiang WQ, Xia Y (2019) Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: a SEER database analysis. Cancer Med 8(3):874–881. https://doi.org/10.1002/cam4.1870. (PMID: 10.1002/cam4.1870307066756434224) Costa LJ, Xavier AC, Wahlquist AE, Hill EG (2013) Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 121(24):4861–4866. https://doi.org/10.1182/blood-2012-12-475558. (PMID: 10.1182/blood-2012-12-475558236410153682339) Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc, Series B 34:187–220. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. (PMID: 10.1080/01621459.1958.10501452) Vincent GK, Velkoff VA (2010) The next four decades, the older population in the United States: 2010 to 2050. In: Current Population Reports. P25-1138. U.S. Census Bureau, Washington, DC. Texas Demographic Center. Projections of the population of Texas and counties in Texas by age, sex, and race/ ethnicity for 2010-2050, 2018 http://demographics.texas.gov/Data/TPEPP/Projections/Methodology.pdf; [accessed 25 February 2022]. Texas Demographic Center (2016) Aging in Texas, Accessed 25 February 2022, https://demographics.texas.gov/resources/publications/2016/2016_06_07_aging.pdf . United States Census Bureau. https://www.census.gov/quickfacts/TX . [accessed 25 February 2022]. Burns EA, Sanchez CG, Mathur S, Guerrero C, Muhsen IN, Sarfraz H, Hu CA, Tang CA, Shah SS, Tremont IW, Teh B, Ganguly S, Pingali SRK (2023) Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry. Ann Hematol 102(5):1111–1120. https://doi.org/10.1007/s00277-023-05140-6. (PMID: 10.1007/s00277-023-05140-636922432) Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, Jabbour E (2021) Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv 5(20):3913–3918. https://doi.org/10.1182/bloodadvances.2021004427 Erratum in: Blood Adv. 2022;6(7):2452. (PMID: 10.1182/bloodadvances.2021004427344649748945626) Howlader N, Shiels MS, Mariotto AB, Engels EA (2016) Contributions of HIV to non-Hodgkin lymphoma mortality trends in the United States. Cancer Epidemiol Biomarkers Prev 25(9):1289–1296. https://doi.org/10.1158/1055-9965.EPI-16-0273. (PMID: 10.1158/1055-9965.EPI-16-027327418269) Issa DE, van de Schans SA, Chamuleau ME, Karim-Kos HE, Wondergem M, Huijgens PC, Coebergh JW, Zweegman S, Visser O (2015) Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica 100(4):525–533. https://doi.org/10.3324/haematol.2014.107300. (PMID: 10.3324/haematol.2014.107300255126434380726) Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, Luu HN (2017) Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer 140(7):1494–1502. https://doi.org/10.1002/ijc.30576. (PMID: 10.1002/ijc.30576280068536919213) Castillo JJ, Winer ES, Olszewski AJ (2013) Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer 119(20):3672–3679. https://doi.org/10.1002/cncr.28264. (PMID: 10.1002/cncr.2826423913575) Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS, UK National Cancer Research Institute Lymphoma Clinical Studies Group, Australasian Leukaemia and Lymphoma Group (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112(6):2248–2260. https://doi.org/10.1182/blood-2008-03-145128. (PMID: 10.1182/blood-2008-03-145128186121022532802) Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR (2020) Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol 38(22):2519–2529. https://doi.org/10.1200/JCO.20.00303. (PMID: 10.1200/JCO.20.00303324536407392744) Crombie J, LaCasce A (2021) The treatment of Burkitt lymphoma in adults. Blood 137(6):743–750. https://doi.org/10.1182/blood.2019004099. (PMID: 10.1182/blood.201900409933171490) Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S (2018) Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 5(12):e609–e617. https://doi.org/10.1016/S2352-3026(18)30177-7. (PMID: 10.1016/S2352-3026(18)30177-7305018686342507) Anand K, Pingali SRK, Ensor JE (2020) Relationship between poverty rate and survival for diffuse large B-cell lymphoma. In: Presented at the American Society of Hematology 62 nd Annual Meeting; Abstract No 3467. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D, UKLG LY06 collaborators (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13(8):1264–1274. https://doi.org/10.1093/annonc/mdf253 Erratum in: Ann Oncol. 2002;13(12):1961. Norbert, P [corrected to Pescosta, N]. (PMID: 10.1093/annonc/mdf25312181251) Thomas DA, Cortes J, O’Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H (1999) Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 17(8):2461–2470. https://doi.org/10.1200/JCO.1999.17.8.2461. (PMID: 10.1200/JCO.1999.17.8.246110561310) Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J (1990) Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8(4):615–622. https://doi.org/10.1200/JCO.1990.8.4.615 Erratum in: J Clin Oncol;12(3):646. (PMID: 10.1200/JCO.1990.8.4.6152313330) Diviné M, Lepage E, Brière J, Pautier P, Dupriez B, Lederlin P, Mineur P, Tilly H, Blanc M, Audhuy B, Herbrecht R, Coiffier B, Reyes F Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis (1996). The Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 14(1):240–248. https://doi.org/10.1200/JCO.1996.14.1.240. Shah BK, Budhathoki N (2016) Second primary malignancy in Burkitt’s lymphoma. Acta Oncol 55(3):396–398. https://doi.org/10.3109/0284186X.2015.1054951. (PMID: 10.3109/0284186X.2015.105495126073448) Della Rocca AM, Tonin FS, Fachi MM, Cobre AF, Ferreira VL, Leonart LP, Steffenello-Durigon G, Del Moral JAG, Lenzi L, Pontarolo R (2021) Prognostic factors, survival analyses and the risk of second primary cancer: a population-based study on Burkitt lymphoma/leukemia. Diseases 9(2):43. https://doi.org/10.3390/diseases9020043. (PMID: 10.3390/diseases9020043342037488293230) |
| فهرسة مساهمة: | Keywords: Burkitt lymphoma; Elderly; Health disparities; Second primary cancer; Survival |
| تواريخ الأحداث: | Date Created: 20230708 Date Completed: 20230911 Latest Revision: 20230915 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1007/s00277-023-05328-w |
| PMID: | 37422592 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-023-05328-w |